Back to Results
First PageMeta Content
Venture capital / Cancer immunotherapy / Immunology / DDX58 / Immune system


Rigontec GmbH raises €4.8m in a second closing of its Series A financing Brings Series A total to €14.25m to advance RNA-based immunotherapeutics for cancer and viral diseases Bonn, Germany. 24th March 2015 – Rigon
Add to Reading List

Document Date: 2015-03-24 04:28:54

Open Document

File Size: 85,30 KB

Share Result on Facebook
UPDATE